A recent development in the healthcare sector has sparked controversy and left many questioning the accessibility of life-changing medications. The removal of a drug assessment from the National Centre for Pharmacoeconomics (NCPE) website has raised concerns about the availability of treatment for a rare muscular condition.
But here's where it gets controversial: the NCPE, an independent body, recommended that a new drug for Duchenne Muscular Dystrophy (DMD) should not be covered by the public healthcare system unless its cost-effectiveness improves. This condition, which primarily affects young boys, has an estimated 50 potential candidates for treatment in Ireland.
The NCPE's assessment of Givinostat, brand name Duvyzat, revealed a staggering cost range of €92,000 to €334,000 per patient annually, depending on weight. This is in stark contrast to the current treatment options, which cost between €10,000 and €15,000 per year. The potential budget impact for the HSE over five years could be as high as €58 million.
And this is the part most people miss: the NCPE is not just a group of experts; they are clinicians, pharmacists, pharmacologists, and statisticians who evaluate the benefits and costs of medical technologies. Their role is crucial in ensuring the sustainability of the healthcare system, but it also means making tough decisions about what treatments are accessible to the public.
The assessment, which was briefly available on the NCPE website, has now been removed at the request of the Department of Health. Professor Michael Barry, NCPE Clinical Director, agreed to its removal, anticipating that the findings would be published soon. However, the detailed technical summary and a simplified version for the public are no longer accessible.
DMD is a progressive condition that leads to muscle weakness, scoliosis, joint contractures, and an increased risk of life-threatening illnesses. Children with DMD often require wheelchairs by the age of 10-12 years. The current treatment includes steroids and various therapies, but Givinostat offers a potential game-changer.
As Minister for Health Jennifer Carroll MacNeill prepares to address the Irish Pharmaceutical Healthcare Association (IPHA) conference, the timing of this development is noteworthy. Especially considering the recent announcement of a new four-year drugs deal between the IPHA and the Government.
The question remains: should cost-effectiveness be the sole determinant of public access to life-saving medications? What are your thoughts on this complex issue? Feel free to share your opinions in the comments below!
